Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas

Abstract excerpt

Abstract Homozygous deletion of CDKN2A/B was recently incorporated into the World Health Organization classification for grade 3 meningiomas. While this marker is overall rare in meningiomas, its relationship to other CDKN2A alterations on a transcriptomic, epigenomic, and copy number level has not yet been determined. We therefore utilized multidimensional molecular data of 1577 meningioma samples from 6...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Glioma Diagnosis and Treatment
• Share to Meningioma and schwannoma management
• Share to Pituitary Gland Disorders and Treatments